Skip to main content

Length of Follow-up Time for New Users of Immunosuppressive Drugs

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    adalimumab
    alemtuzumab
    certolizumab
    dalfampridine
    dimethyl fumarate
    etanercept
    fingolimod
    glatiramer acetate
    golimumab
    infliximab
    interferon beta-1A
    interferon beta-1B
    mitoxantrone
    natalizumab
    pegylated interferon beta-1A
    teriflunomide
    ustekinumab
    Description

    This report contains estimates of the length of follow-up time for new users of immunosuppressive drugs (adalimumab, alemtuzumab, certolizumab, dalfampridine, dimethyl fumarate, etanercept, fingolimod, glatiramer acetate, golimumab, infliximab, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, pegylated intereferon beta-1A, teriflunomide, and ustekinumab) and for patients diagnosed with Crohn's disease, multiple sclerosis, psoriasis, and ulcerative colitis in the Sentinel Distributed Database (SDD). This report was distributed to Data Partners on June 30, 2017. 

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2000 - June 30, 2017
    Analysis Type
    Retrospective Inferential
    Population / Cohort
    Individuals 18 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)